Obstructive colorectal cancer is associated with substantial morbidity and stoma formation. Bridge-to-surgery (BTS) using self-expanding metallic stents (SEMS) can convert emergency surgery into an elective procedure, but evidence in robotic colorectal surgery remains limited. This study evaluated the feasibility of SEMS-based BTS in robotic surgery for obstructive left-sided colorectal cancer. This retrospective single-center cohort study included consecutive patients who underwent robotic colorectal resection between February 2023 and December 2025. After excluding right-sided colon cancer, 161 patients were analyzed: 37 underwent BTS and 124 underwent upfront elective surgery. Propensity score matching using preoperative variables generated 36 matched pairs. The primary outcome was major postoperative complications, defined as Clavien–Dindo grade ≥ III complications. Secondary outcomes included perioperative outcomes, robotic intraoperative metrics, and short-term oncological surrogate outcomes. After matching, robotic intraoperative metrics showed no statistically significant differences between the non-BTS and BTS groups, including console time (136.50 vs. 148.00 min, P = 0.166), total operative time (250.00 vs. 274.50 min, P = 0.205), estimated blood loss (3.00 vs. 3.00 mL, P = 0.936), and conversion to open surgery (0
The double bipolar method (DBM) using Maryland and fenestrated bipolar forceps has been advocated as a bipolar-centered energy strategy for robotic colorectal surgery; however, evidence beyond small case series is limited. This study therefore evaluated the feasibility, safety, and learning curve of DBM in a consecutive single-institution cohort. We retrospectively analyzed 100 consecutive robotic colorectal resections performed using DBM between June 2023 and September 2025. The primary endpoint was operative time and its learning curve, assessed using the cumulative sum (CUSUM) and segmented regression. Key safety endpoints—anastomotic leakage and major complications (Clavien–Dindo ≥ III)—were summarized descriptively. Secondary endpoints included blood loss, conversion, length of stay, and readmission. Sensitivity analyses employed risk-adjusted CUSUM. The mean operative time was 244 min, and the median blood loss was 3 mL. No cases required conversion to open surgery. Anastomotic leakage and major complications were observed in 0
BACKGROUND:Baseline exposure to antibiotics and proton pump inhibitors has been associated with reduced efficacy of immune checkpoint inhibitors in patients with advanced tumours, possibly through gut microbiome disruption. Whether this outcome extends to those with earlier-stage disease remains unclear. We aimed to assess the association of baseline antibiotics and proton pump inhibitors with progression-free survival and overall survival in patients with unresectable stage III non-small cell lung cancer (NSCLC). METHODS:PACIFIC was a randomised, double-blind, placebo-controlled phase 3 trial done in patients aged 18 years or older with unresectable stage III squamous or non-squamous NSCLC, WHO performance status 0-1, and no progression after two or more cycles of concurrent chemoradiotherapy. Patients were randomly assigned (2:1) to durvalumab 10 mg/kg intravenously every 2 weeks for up to 12 months or placebo, starting 1-42 days after chemoradiotherapy; patients were stratified by age, sex, and smoking history. This post-hoc analysis was based on the final 5-year data cutoff date of the completed trial and included the treated population with consent for exploratory analyses. Co-primary endpoints were progression-free survival and overall survival, assessed according to baseline exposure to proton pump inhibitors and systemic antibiotics. This trial is registered on ClinicalTrials.gov (NCT02125461). FINDINGS:Between May 9, 2014, and April 22, 2016, 713 patients were randomly assigned; 660 were included in this post-hoc analysis, of whom 449 received durvalumab and 211 received placebo; 203 (30·8%) were female and 453 (68·6%) were male. Race was reported as Asian in 153 (23·1%) patients, Black or African American in five (0·7%), White in 424 (64·2%), and unknown in 78 (11·8%). Baseline proton pump inhibitor exposure was recorded in 263 (40%) of 660 patients and antibiotic exposure was recorded in 69 (10%). Median follow-up in the pooled population was 62·4 (IQR 61·9-63·2) months. In the durvalumab group baseline exposure to proton pump inhibitors was associated with shorter progression-free survival (9·4 months [95% CI 7·6-13·7] vs 17·2 months [15·4-23·2]; hazard ratio [HR] 1·57 [95% CI 1·28-1·93]; p<0·0001) and overall survival (33·0 months [95% CI 21·9-46·7] vs 57·9 months [48·7-not computable (NC)]; HR 1·66 [95% CI 1·30-2·13]; p<0·0001) compared to no exposure to proton pump inhibitors, while baseline exposure to antibiotics was associated with shorter progression-free survival (9·2 months [95% CI 4·9-18·1] vs 15·6 months [13·6-17·6]; HR 1·50 [95% CI 1·08-2·10]; p=0·016) compared to no exposure to antibiotics, but there was no significant change in overall survival (37·7 months [95% CI 18·8-NC; 28 events] vs 49·2 months [39·7-57·3]; HR 1·33 [95% CI 0·90-1·97]; p=0·16). In the placebo group, neither proton pump inhibitor exposure nor antibiotic exposure was associated with changes in progression-free survival and overall survival. Interactions between treatment and proton pump inhibitors for progression-free survival (p=0·023) and overall survival (p<0·0001) were significant, but not for antibiotics. INTERPRETATION:Baseline exposure to proton pump inhibitors and antibiotics was associated with inferior outcomes with durvalumab, but not with placebo, consistent with potential attenuation of the benefit of durvalumab with proton pump inhibitors and antibiotics in patients with unresectable stage III NSCLC. FUNDING:None.
BACKGROUND:Selecting the optimal WATCHMAN FLX (a second-generation left atrial appendage [LAA] closure device) size for a borderline-sized LAA, for which 2 device sizes are acceptable, remains challenging. OBJECTIVES:The aim of this study was to evaluate how device size affects procedural and clinical outcomes in borderline-sized LAAs undergoing LAA closure. METHODS:From the Japanese multicenter TERMINATOR (Transcatheter Modification of Left Atrial Appendage by Obliteration with Device in Patients With NVAF) registry, 1,190 patients who underwent LAA closure with the second-generation device between May 2021 and September 2023 were reviewed. Of these, 757 with borderline-sized LAAs were included and categorized into large (n = 390) and small (n = 367) device groups. The median follow-up duration was 274 days (Q1-Q3: 100-368 days). Outcomes included peridevice leak (PDL), all-cause mortality, ischemic cerebrovascular accident or systemic embolism, major bleeding, and device-related thrombus. RESULTS:PDL occurred less frequently in the large device group compared with the small device group (1.54% [6 of 390] vs 4.90% [18/367]; P = 0.015). Ischemic cerebrovascular accident or systemic embolism was lower in the large device group (8.4% [95% CI: 1.8%-34.1%] vs 10.5% [95% CI: 3.6%-28.4%]; P = 0.036). No significant difference was observed in all-cause mortality (15.2% [95% CI: 6.0%-35.7%] vs 12.3% [95% CI: 4.6%-30.6%]; P = 0.288), major bleeding (4.5% [95% CI: 2.6%-7.7%] vs 15.7% [95% CI: 4.3%-48.7%]; P = 0.570), or device-related thrombus (8.6% [95% CI: 3.2%-22.2%] vs 3.2% [95% CI: 1.6%-6.4%]; P = 0.603). CONCLUSIONS:In borderline-sized LAAs, the larger device was associated with fewer PDLs and ischemic events without increased procedural risk.
BACKGROUND:The efficacy and safety of early direct oral anticoagulant (DOAC) (re)initiation in patients with non-valvular atrial fibrillation (NVAF) after acute onset of intracranial hemorrhage (ICH) are unknown. This study evaluated ischemic and hemorrhagic risks following early DOAC (re)initiation after ICH in patients with NVAF. METHODS AND RESULTS:SAFE-ICH is a multicenter prospective observational single-arm registry study at 32 Japanese hospitals. Eligible patients had NVAF, were aged ≥20 years, and (re)initiated DOAC ≤14 days following symptomatic ICH. Among 240 patients who (re)initiated DOAC (61.3% male; mean [±SD] age 79.4±9.3 years), intraparenchymal hemorrhage predominated (84.6%), followed by subdural (12.9%), intraventricular (1.7%), and epidural (0.8%) hemorrhage. The median (interquartile range) baseline National Institutes of Health Stroke Scale score was 10 (3-16) and time to DOAC (re)initiation was 7 days (5-10 days). Edoxaban, apixaban, and rivaroxaban were used in 55.0%, 35.8%, and 9.2% of patients, respectively. The primary endpoint (composite of symptomatic ICH, any stroke, or death ≤30 days following DOAC [re]initiation) occurred in 12 (5.0%) patients. There were 4 recurrent ICH events (1.7%; all recurrent subdural hemorrhages). Five (2.1%) patients died of non-vascular causes. CONCLUSIONS:In Japanese patients with NVAF, early DOAC (re)initiation ≤14 days after ICH appears to have an acceptable risk for ischemic and hemorrhagic events, particularly in patients with intraparenchymal hemorrhage. In patients with subdural hematoma, early DOAC (re)initiation requires vigilant monitoring.